Parsimonious Models for Survival Data

Information

  • Research Project
  • 8545192
  • ApplicationId
    8545192
  • Core Project Number
    R43GM101729
  • Full Project Number
    5R43GM101729-02
  • Serial Number
    101729
  • FOA Number
    PAR-09-220
  • Sub Project Id
  • Project Start Date
    9/14/2012 - 12 years ago
  • Project End Date
    2/28/2015 - 9 years ago
  • Program Officer Name
    SHEELEY, DOUGLAS
  • Budget Start Date
    9/1/2013 - 11 years ago
  • Budget End Date
    2/28/2015 - 9 years ago
  • Fiscal Year
    2013
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/27/2013 - 11 years ago
Organizations

Parsimonious Models for Survival Data

DESCRIPTION (provided by applicant): This Small Business Innovation Research project addresses the problem of biomarker detection in clinical and high-throughput data. The objective is to investigate new approaches for deter- mining, from data consisting of many possibly irrelevant or redundant measurements, a highly predictive and interpretable model that involves only a small number of measurements. These new methods will be studied for modeling subjects' time-to-event (such as stroke, heart attack, or metastasis in cancer). The proposed approaches will be compared with existing methods that attempt to use relatively few mea- surements in modeling survival (time-to-event) data. The data to be analyzed will include ion-mobility and clinical data from a large cardiovascular disease cohort, as well as high-throughput genomic data from cancer research with many more measurements than samples. Relevance. Although today's advanced technologies offer the possibility of revolutionizing clinical practice, the analytical tools available for extracting information from this amount of daa are not yet sufficiently developed for targeted exploration of the underlying biology. This project directly addresses the need to make what the FDA terms IVDMIA (In-Vitro Diagnostic Multivariate Index Assays) transparent and interpretable, and is thus an opportunity to improve analysis services or products provided to companies that identify, characterize, and validate biomarkers for clinical diagnostics and drug development decision points. The proposed project will produce robust methods for parsimonious biomarker detection that will speed the development of cheaper and more effective diagnostic tests for disease diagnosis, treatment monitoring, and therapeutic drug development.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    72751
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:72751\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INSILICOS
  • Organization Department
  • Organization DUNS
    126643241
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981094955
  • Organization District
    UNITED STATES